
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
Author(s) -
Tania M. Welzel,
David R. Nelson,
Giuseppe Morelli,
Adrian Di Bisceglie,
Rajender Reddy,
Alexander Kuo,
Joseph K. Lim,
Jama M. Darling,
Paul J. Pockros,
Joseph Galati,
Lynn M. Frazier,
Saleh A. Alqahtani,
Mark S. Sulkowski,
Monika Vainorius,
Lucy Akushevich,
Michael Fried,
Stefan Zeuzem
Publication year - 2017
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/v2jq-xc82
Subject(s) - sofosbuvir , ribavirin , genotype , virology , medicine , hepatitis c virus , biology , virus , genetics , gene